Coya Therapeutics Files 8-K: Material Agreement & Equity Sales
Ticker: COYA · Form: 8-K · Filed: May 20, 2024 · CIK: 1835022
| Field | Detail |
|---|---|
| Company | Coya Therapeutics, Inc. (COYA) |
| Form Type | 8-K |
| Filed Date | May 20, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $8.29, $5.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, disclosure
TL;DR
Coya Therapeutics signed a big deal and sold some stock, filing an 8-K on 5/17.
AI Summary
On May 17, 2024, Coya Therapeutics, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company also reported on unregistered sales of equity securities and provided a Regulation FD disclosure. This filing also includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity for Coya Therapeutics, including a material definitive agreement and equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing mentions a material definitive agreement and unregistered sales of equity securities, which can introduce financial and operational risks.
Key Players & Entities
- Coya Therapeutics, Inc. (company) — Registrant
- May 17, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement entered into by Coya Therapeutics?
The specific details of the Material Definitive Agreement are not disclosed in this 8-K filing, but its entry is reported as a significant event.
When did Coya Therapeutics report the unregistered sales of equity securities?
The 8-K filing reports on unregistered sales of equity securities, with the earliest event reported on May 17, 2024.
What other items are included in this 8-K filing besides the material agreement?
This 8-K filing also includes information on unregistered sales of equity securities, Regulation FD disclosure, and financial statements and exhibits.
What is Coya Therapeutics' principal executive office address?
Coya Therapeutics' principal executive offices are located at 5850 San Felipe St., Suite 500, Houston, Texas 77057.
What is the SEC file number for Coya Therapeutics?
The SEC file number for Coya Therapeutics is 001-41583.
Filing Stats: 792 words · 3 min read · ~3 pages · Grade level 10.4 · Accepted 2024-05-20 17:00:35
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share COYA The Nasdaq Stock Mar
- $8.29 — "Common Stock"), at a purchase price of $8.29 per share for gross proceeds to the Com
- $5.0 million — re for gross proceeds to the Company of $5.0 million. Pursuant to the Purchase Agreement,
Filing Documents
- d820823d8k.htm (8-K) — 26KB
- d820823dex101.htm (EX-10.1) — 275KB
- d820823dex991.htm (EX-99.1) — 27KB
- 0001193125-24-142950.txt ( ) — 537KB
- coya-20240517.xsd (EX-101.SCH) — 3KB
- coya-20240517_lab.xml (EX-101.LAB) — 18KB
- coya-20240517_pre.xml (EX-101.PRE) — 11KB
- d820823d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COYA THERAPEUTICS, INC. Date: May 20, 2024 By: /s/ Howard Berman Howard Berman Chief Executive Officer